Current controversies in the management of metastatic colorectal cancer Ruth VeraVicente AlonsoManuel Valladares-Ayerbes Review Article 26 June 2015 Pages: 659 - 677
Are pharmacogenomic biomarkers an effective tool to predict taxane toxicity and outcome in breast cancer patients? Literature review Francesca De IuliisGerardo SalernoSusanna Scarpa Review Article 22 July 2015 Pages: 679 - 690
Outcomes for newly diagnosed patients with acute myeloid leukemia dosed on actual or adjusted body weight Whitney M. BrayCory BivonaTara L. Lin Original Article 01 August 2015 Pages: 691 - 697
Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration Nianhang ChenCarrie BrachmannRajesh Chopra Original Article Open access 01 August 2015 Pages: 699 - 712
Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug–drug interaction Masanori MotonagaNoboru YamamotoYoshikazu Hayashi Original Article 02 August 2015 Pages: 713 - 721
Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours Ruth PlummerHelen SwaislandL. Rhoda Molife Original Article 05 August 2015 Pages: 723 - 729
Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer G. Quintero-AldanaM. JorgeB. Campos Balea Original Article 05 August 2015 Pages: 731 - 737
Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer Hirofumi MukaiNorikazu MasudaYuichi Ando Original Article 08 August 2015 Pages: 739 - 750
Absorption, distribution, metabolism, and excretion of [14C]BYL719 (alpelisib) in healthy male volunteers Alexander JamesLars BlumensteinPiet Swart Original Article 08 August 2015 Pages: 751 - 760
First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations Tomohito KuwakoHisao ImaiMasanobu Yamada Original Article 08 August 2015 Pages: 761 - 769
Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents Takehito ShukuyaRyo KoKazuhisa Takahashi Original Article 11 August 2015 Pages: 771 - 776
A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer Robin L. JonesJohanna C. BendellKathleen N. Moore Original Article 18 August 2015 Pages: 777 - 784
A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours B. VenugopalA. AwadaS. Aamdal Original Article 20 August 2015 Pages: 785 - 792
A clinical pharmacokinetic microdosing study of docetaxel with Japanese patients with cancer Ken-ichi FujitaEtsuko YoshinoYasutsuna Sasaki Original Article 22 August 2015 Pages: 793 - 801
Oral and intravenous pharmacokinetics of 5-fluoro-2′-deoxycytidine and THU in cynomolgus monkeys and humans Julianne L. HolleranJan H. BeumerJulie L. Eiseman Original Article 01 September 2015 Pages: 803 - 811
Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib John F. DeekenJan H. BeumerMichelle A. Rudek Original Article 02 September 2015 Pages: 813 - 819
PLGA nanoparticle formulation of RK-33: an RNA helicase inhibitor against DDX3 Guus Martinus BolRaheela KhanVenu Raman Original Article 02 September 2015 Pages: 821 - 827
Cetuximab plus pemetrexed as second-line therapy for fluorouracil-based pre-treated metastatic esophageal squamous cell carcinoma Jing TianMing ShangJun Xu Original Article 02 September 2015 Pages: 829 - 834
EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer Kyoko OtsukaAkito HataNobuyuki Katakami Original Article 08 September 2015 Pages: 835 - 841
A phase I study of volasertib combined with afatinib, in advanced solid tumors Jean-Pascal MachielsMarc PeetersSylvie Rottey Original Article 08 September 2015 Pages: 843 - 851
Overcoming ABCG2-mediated drug resistance with imidazo-[1,2-b]-pyridazine-based Pim1 kinase inhibitors Richard A. J. DarbyAmanda UnsworthRichard Callaghan Original Article 09 September 2015 Pages: 853 - 864
Influence of infusion method on gemcitabine pharmacokinetics: a controlled randomized multicenter trial Nicolas SimonOlivier RomanoPascal Odou Clinical Trial Report 21 July 2015 Pages: 865 - 871
Whole-brain radiation fails to boost intracerebral gefitinib concentration in patients with brain metastatic non-small cell lung cancer: a self-controlled, pilot study Luo FangXiaojiang SunNengming Lin Short Communication 27 August 2015 Pages: 873 - 877
